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Abstract
Background—TB remains a major public health concern, even in low-incidence countries like 
the USA and the UK. Over the last two decades, cases of TB reported in the USA have declined, 
while they have increased substantially in the UK. We examined factors associated with this 
divergence in TB trends between the two countries.
Methods—We analysed all cases of TB reported to the US and UK national TB surveillance 
systems from 1 January 2000 through 31 December 2011. Negative binominal regression was 
used to assess potential demographic, clinical and risk factor variables associated with differences 
in observed trends.
Findings—A total of 259 609 cases were reported. From 2000 to 2011, annual TB incidence 
rates declined from 5.8 to 3.4 cases per 100 000 in the USA, whereas in the UK, TB incidence 
increased from 11.4 to 14.4 cases per 100 000. The majority of cases in both the USA (56%) and 
the UK (64%) were among foreign-born persons. The number of foreign-born cases reported in 
the USA declined by 15% (7731 in 2000 to 6564 in 2011) while native-born cases fell by 54% 
(8442 in 2000 to 3883 in 2011). In contrast, the number of foreign-born cases reported in the UK 
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increased by 80% (3380 in 2000 to 6088 in 2011), while the number of native-born cases 
remained largely unchanged (2158 in 2000 to 2137 in 2011). In an adjusted negative binomial 
regression model, significant differences in trend were associated with sex, age, race/ethnicity, site 
of disease, HIV status and previous history of TB (p<0.01). Among the foreign-born, significant 
differences in trend were also associated with time since UK or US entry (p<0.01).
Interpretation—To achieve TB elimination in the UK, a re-evaluation of current TB control 
policies and practices with a focus on foreign-born are needed. In the USA, maintaining and 
strengthening control practices are necessary to sustain the progress made over the last 20 years.
INTRODUCTION
The USA and UK are low TB incidence countries, defined as countries with an annual TB 
incidence rate of <20 cases per 100 000 population.12 Both countries are considered high 
income nations,3 with good population health indicators.45 In the last decade, the USA and 
UK ranked first and fourth, respectively, on a list of nations with largest numbers of 
migrants.6 On average, one million immigrants per annum settled in the USA and 400 000 
settled in the UK.6
In spite of similarities in economic, population health and migration indices, trends in annual 
reported TB case counts and incidence rates in the USA and the UK have been diverging. 
Both countries experienced parallel declines through the late 1980s. In 1992, both countries 
reported approximately 10 TB cases per 100 000.78 Since then, the USA has reported 22 
consecutive years of annual TB decline, culminating in the lowest reported TB incidence 
rate in its history of 3.0 cases per 100 000 in 2013.8
In contrast, TB rates in the UK increased steadily over the last 20 years with a peak of 14.4 
cases per 100 000 recorded in 2009,7 which declined to 12.3 per 100 000 in 2013.7 The 
factors associated with this divergence in trends are not clear. Several studies attribute rising 
TB rates to a combination of an increased number of TB cases and reactivation of latent 
infection among immigrants in UK.9–12 In the USA, the decline in annual TB rates has been 
attributed to ongoing improvements in TB control practices and a decline in incidence 
among the foreign-born.813–15
In this study, we examined trends in the number of reported TB cases and incidence rates 
between the USA and the UK from 2000 through 2011 with a focus on the demographic and 
clinical characteristics that may help explain the differing trends between these two 
countries—and therefore, inform future TB prevention and control efforts in both countries.
METHODS
We included all TB cases reported in the USA and the UK from 1 January 2000 through 31 
December 2011. TB cases in the USA were reported to the US National Tuberculosis 
Surveillance System from all 50 US states and the District of Columbia. TB cases in the UK 
were reported to the Enhanced Tuberculosis Surveillance System. Using standardised case 
reporting definitions, demographic, clinical and social risk factor data were collected on 
each patient as part of routine surveillance as described elsewhere.1617 TB incidence (case) 
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rates were calculated by dividing the annual reported number of TB cases by the appropriate 
mid-year population estimate obtained from the Intercensal Estimates of the Resident 
Population of the USA,18 the US Current Population Survey19 or the UK Office of National 
Statistics.20 Race/ethnicity groups from the USA and the UK were recoded into four groups 
to harmonise classification systems between countries: Asian, black, white and other. 
Hispanic, Native Hawaiian/Alaska Native, American Indian and mixed race groups in the 
USA were recorded as ‘Other’. In the UK, Indian, Pakistani, Bangladeshi and Chinese race/
ethnicity groups were recorded as Asian; black African, black Caribbean and black other 
groups were recorded as black; and the mixed race group was retained as ‘Other’. HIV test 
result data in the USA were available as negative, positive, indeterminate, unknown, refused 
and test done but results unknown. In the UK, HIV data were available only as a 
dichotomous variable; positive and not known to be positive. Therefore, HIV for the USA 
was dichotomised accordingly to allow for direct comparison between the two countries. 
Among foreign-born, time from US or UK entry to TB diagnosis was categorised into four 
classes: <2 years, 2–5 years, 6–9 years and ≥10 years. Multidrug-resistant TB (MDR-TB) 
was defined as antituberculosis drug resistance to at least isoniazid and rifampicin.
Statistical analysis
We used JoinPoint with Monte Carlo permutation significance testing21 to estimate the 
annual per cent change (APC) in TB case rates over time and the year significant rate 
changes occurred. To estimate the trends in TB case counts, we used negative binomial 
regression analysis to model the APC for the different population subgroups.21–25 Our final 
model included the following variables: place of birth, sex, age group, previous history of 
TB, site of disease, race/ethnicity, HIV status and time since entry among US or UK 
foreign-born. We conducted a stratified regression analysis with a three-way interaction 
model including the number of cases by report year in each reporting country and each of 
several variables under consideration, such as site of disease (exclusively pulmonary, 
exclusively extrapulmonary or both) and place of birth (US or UK foreign-born, US or UK 
native-born). Additional negative binomial models were used to assess trends by time from 
entry to TB diagnosis among the foreign-born and HIV coinfection. We calculated empirical 
estimates of annualised per cent change ((case count for 2011/case count for 
2000)(1/11)×100) for comparison with model estimates. Because only non-identifiable, 
routinely collected surveillance data were used, the study did not require human subjects 
review.
RESULTS
Demographic and selected clinical characteristics
A total of 259 609 TB cases, including 163 837 cases in the USA and 95 772 cases in the 
UK, were reported from 2000 through 2011 (table 1). In the USA, 62% of cases were male, 
the median age was 44 years (IQR=29–60 years); half of all reported cases were in the 
oldest age group (aged 45 years and older). The proportion of reported cases by race/
ethnicity was as follows: Asian, 24%; black, 28%; white, 18% and ‘Other’, 30% (table 1). 
The vast majority (93%) of cases of ‘Other’ were persons of Hispanic ethnicity. Nearly 70% 
of the cases had exclusively pulmonary disease, 21% had exclusively extrapulmonary 
Nnadi et al. Page 3
Thorax. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
disease and 9% had both. Nearly 8% of the cases were known to be HIV positive at the time 
of TB diagnosis.
In the UK, 55% of cases were male, the median age was 36 years (IQR=26–53 years); the 
majority of cases (59%) were in 15–44 years age group. The approximate proportions of 
reported cases by race/ethnicity were as follows: Asian, 40%; black, 23%; white, 24% and 
‘Other’ or unknown 13% (table 1). Less than half (47%) of the cases had exclusively 
pulmonary disease, nearly 44% were exclusively extrapulmonary and 9% had both. 
Approximately, 5% of the cases were known to be HIV positive at the time of TB reporting.
Trends in TB incidence rate
There were significant trend differences in reported TB cases between the USA and the UK 
during 2000–2011 (figure 1). In the USA, TB case counts declined from 16 309 to 10 528, 
while rates declined from 5.8 to 3.4 cases per 100 000. Significant declines in overall US TB 
incidence rates were observed during 2000–2007 (APC=−3.7, p<0.001), followed by more 
rapid declines during 2008–2011 (APC=−6.6, p<0.001). In the UK, annual TB case counts 
increased from 6724 to 8963 and incidence rates increased from 11.4 to 14.4 cases per 100 
000. We found significant increases in overall UK rates during 2000–2005 (APC=+3.4, 
p<0.001) followed by a period of relatively stable rates during 2006–2011 (APC=+0.2, 
p=0.78).
Trends in TB incidence rates—native-born persons
In 2000, US native-born case rates (3.5 per 100 000) were comparable with UK native-born 
case rates (4.2 per 100 000) (figure 2). From 2000 through 2011, US native-born rates fell 
by 57% with the greatest rate of decline observed during 2000–2002 (APC=−9.1, p<0.001). 
Further declines were observed during 2003–2006 (APC=−5.6, p<0.001) and 2007–2011 
(APC=−8.3, p<0.001). In contrast, UK native-born incidence rates remained unchanged over 
the same period (APC=0.00, p=0.91).
Trends in TB incidence rates—foreign-born persons
A decline in case rates (from 27.1 to 17.1 per 100 000) was observed among the US foreign-
born during 2000–2011 (APC=−4.3, p<0.001) (figure 3). The country of birth varied greatly 
among foreign-born TB cases diagnosed in the USA (number of known birth 
countries=209). Persons with TB born in five countries (Mexico, Philippines, Vietnam, India 
and China) made up 55.2% of all foreign-born cases in the USA. Annualised TB case counts 
and incidence rates among foreign-born persons by country of birth in the USA are 
presented in online supplementary table S1. Among the UK foreign-born, there was an 
increase in case rates from 77.2 to 98.6 per 100 000 during 2000–2005 (APC=+6.0, 
p<0.001) followed by a decline to 83.6 per 100 000 in 2011 (APC=−2.2, p<0.001). The 
country of birth also varied among foreign-born TB cases diagnosed in the UK (number of 
known birth countries=206). Five countries (India, Pakistan, Bangladesh, Somalia and 
Zimbabwe) contributed 61% of all foreign-born cases. Annualised TB case counts and 
incidence rates among foreign-born persons by country of birth in the UK are presented in 
online supplementary table S2.
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Trend analysis of TB case counts
A total of 248 005 cases including 162 763 (99%) cases from the USA and 85 242 (90%) 
cases from the UK were included in the analysis. The rest were excluded due to missing 
variables. Sex, race/ethnicity, age group, site of disease, previous TB history, HIV status and 
time from entry to disease diagnosis among the foreign-born were significantly associated 
with differences in trend between the USA and the UK (table 2).
Age group was associated with divergent TB incidence trends between the USA and the UK. 
In the USA, case counts declined across all nativity and age groups, except in foreign-born 
persons in the 45 years and older age group, which remained unchanged. In the UK, 
increases were observed across all nativity and age groups, except among native-born 45 
years and older group where a decline was observed.
Race/ethnicity was associated with differences in TB incidence trends. There were 
substantial declines in TB case counts across all race groups, with the exception of the US-
born Asian group, where an increase was observed. In contrast, declines in case counts in 
the UK were limited to the native-born white group.
Site of disease was associated with differences in overall TB trends. In the USA, there were 
declines in the number of exclusively pulmonary and exclusively extrapulmonary TB cases 
in both foreign-born and native-born, with the exception of a slight (2%) increase among 
foreign-born cases diagnosed with both pulmonary and extrapulmonary disease. In the UK, 
cases of exclusively extrapulmonary TB more than doubled in number among the foreign-
born. There was a small decline (−1.0 APC) in the number of native-born pulmonary cases, 
but broad increases in the number of cases with both extrapulmonary and pulmonary disease 
presentation among both foreign-born and native-born groups.
HIV status was associated with changes in TB incidence trends. Coinfected TB–HIV case 
counts declined from peaks observed through the mid-2000s (highest annual count=485 (7% 
among all cases) in 2004) in the UK. In the USA, there were significant and consistent 
declines in TB–HIV case counts from 2000 through 2011.
Among the foreign-born, time from US or UK entry to TB diagnosis was associated with 
diverging TB trends. While the number of cases diagnosed within 2 years of entry fell by 
44% in the USA, it rose nearly 59% in the UK. TB case counts increased among all UK 
foreign-born time since arrival categories, with the largest increases observed among 
persons diagnosed within 2–5 years (150%) and 6–9 years (183%) from arrival. In contrast, 
in the USA, declines in case counts were observed across all foreign-born cases with the 
exception of persons diagnosed after >10 years in the USA, in which a 10% increase was 
observed.
DISCUSSION
Our analysis describes the similarities and contrasts in TB trends between the UK and the 
USA. In both countries, the proportion of TB cases attributed to the foreign-born was on the 
rise, reflecting patterns observed in many immigrant-receiving countries.2627 However, 
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while TB among the foreign-born remains a major challenge in both countries, we observed 
striking contrasts in TB trends among both foreign-born and native-born.
Among the foreign-born, a significant divergence in TB trends was observed. This 
divergence may be explained in part by differences in migration patterns over the past 
decade. Differing migration patterns is of particular importance, given that in the first few 
years following arrival, foreign-born TB rates may approximate rates in originating regions 
of the world.28 While the largest proportion of US migrants in the last decade originated 
from Latin American countries with relatively low TB burden,129 the UK recorded 
substantial increases in migration from South Asia and Sub-Saharan Africa—regions with 
some of the highest TB burdens in the world.130 Some of the observed differences in trends 
may, therefore, be a reflection of the disparate burdens among major migrant groups in the 
USA relative to the UK. However, with few exceptions, the annualised TB incidence rates 
among foreign-born persons from the top 10 countries of birth now living in the USA tended 
to be lower than the rates in their countries of birth (see online supplementary table S1); 
while the annualised rates among foreign-born persons from the top 10 countries of birth 
now living in the UK were observed to match or exceed the rates in their countries of birth 
(see online supplementary table S2). For example, in 2011, persons from Mexico accounted 
for the largest proportion of TB cases among foreign-born persons in the USA. The 
incidences rate among these persons was 12 per 100 000 (almost half the rate of persons 
living in Mexico (see online supplementary table S1). Whereas in the UK, persons from 
India accounted for the largest proportion of TB among foreign-born persons in the UK. The 
incidence rate among these persons was 253 per 100 000 (36% greater than the rate of 
persons living in India) (see online supplementary table S2). It is worth noting that in 2011, 
India-born persons and Philippine-born persons living in the USA had a lower TB incidence 
than their counterparts living in the UK and in the country of birth (27 vs 253 per 100 000; 
44 vs 91 per 100 000, respectively). This suggests that migration rates alone may not 
account for all differences and more complex factors could potentially be at play.
Differences in time from arrival to TB diagnosis were observed to significantly contribute to 
the diverging trends. Cases diagnosed within the first 2 years of arrival have distinct clinical 
and epidemiological importance, as they most likely represent imported disease. In a recent 
prearrival and postarrival evaluation of a cohort of US immigrants, >80% of TB cases 
diagnosed within 1 year of receiving prearrival examination had radiological evidence of TB 
and represented imported TB cases.31 Our study found that during 2000–2011, the number 
of US foreign-born cases diagnosed within 2 years of arrival declined by 44%. In contrast, 
UK cases diagnosed within the same time frame increased by nearly 60%, signifying 
increases in the number of TB cases in new UK arrivals. The observed decline in imported 
cases of TB among US migrants during this period may represent gains from the 
contemporaneous strengthening of US prearrival TB screening policy, transitioning from 
requiring an evidence of negative sputum smears to the more stringent standard of negative 
sputum culture results, for all intending US immigrants.1527 But it may also reflect 
diminishing TB burdens in key US immigrant-originating countries.132 In the UK, TB 
screening practices during this period, in contrast, was largely limited to chest X-ray-based 
screening of selected migrants at two major airports, as well as screening of a smaller 
number of refugees and asylum seekers already in the country. The increases in cases among 
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UK recent arrivals may thus represent a large number that could have been prevented 
through a more effective prearrival screening programme. Interestingly, recent data from 
Public Health England suggests rates in the UK are now declining due to changes in source 
countries of migrants as well as implementation of a pre-entry screening programme similar 
to the US model which prevented >400 cases in 2014 (PHE 2015 TB Annual Report).
Results from this study and others, where the majority of foreign-born cases may represent 
reactivation of latent TB infection (LTBI) acquired prior to migration,3133 highlight the 
limitation of current approaches to TB prevention in which LTBI testing and treatment 
strategies have yet to be fully implemented.3435 Overall, UK foreign-born cases had shorter 
(4 years) median time from entry to diagnosis compared with US cases (6 years). Whether 
this shorter time to diagnosis in UK immigrants indicates a more rapid progression to 
disease, a higher burden of disease in the first year from entry time, or increased disease 
transmission within the UK are points worthy of further inquiry.
In contrast to US foreign-born, UK foreign-born had a twofold increase in exclusively 
extrapulmonary cases. Potential explanations for this increase may include a selective 
susceptibility to extrapulmonary disease especially among key UK ethnic groups.3637 In the 
setting of a relatively low culture case confirmation, this trend may also represent possible 
excess clinical diagnoses of extrapulmonary TB in the UK population. It is imperative to 
note that while cases of exclusively extrapulmonary disease may not be associated with 
subsequent in-country transmission, they would likely evade detection by the chest X-ray-
based pre-entry screening programme currently in use for UK entrants.
Against the backdrop of an increasing proportion of foreign-born cases, TB prevention and 
control efforts in many low-incidence countries have shifted, appropriately, towards a focus 
on immigrant populations.817 Nevertheless, continued vigilance over TB control among the 
native-born in these countries is still needed. In the UK, the increasing incidence among the 
foreign-born has been the subject of a great deal of inquiry,3638 with little attention paid to 
the relatively unchanged indices among the native-born. Although the absolute numbers are 
smaller in comparison with cases among the foreign-born, our analysis raises concerns about 
the non-decline among the UK native-born, especially in the context of the rapid declines 
among the US native-born. Our analysis further suggests that the stagnating indices among 
the UK native-born are largely driven by increases among minority ethnic groups, although 
the underlying factors behind this trend are not entirely clear. Future research and 
interventions may focus on identifying and interrupting recent transmission, including 
increased household transmission from migrant parents to native-born children3940 or 
transmission that occurs during extended visits to high-burden TB countries.3541
In prioritising public health action, both UK and USA have implemented a TB control 
strategy targeting three main population groups—intending immigrants prior to arrival, 
persons from high burden areas and at-risk native-born groups.
First, finding and treating TB cases among intending immigrants prior to arrival may 
prevent most TB cases. Although the USA has an established prearrival TB screening 
programme, current screening practices cover only refugees and persons seeking permanent 
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residency and are primarily focused on active case finding, and not detection and treatment 
of LTBI.42 Similarly until very recently, only a select group of migrants from high-burden 
TB countries were screened on arrival in the UK.13 The UK has now adopted a prearrival 
immigrant screening programme that covers intending migrants, including students and 
other long-term visitors.38 In a similar way, in USA it would be important to evaluate the 
feasibility of expanding the current screening programme in order to further reduce potential 
cases among migrant groups not currently covered (eg, students and long-term visitors).43 
Because a substantial proportion of future cases may emerge from activation of LTBI,3033 
the value and feasibility of identifying and treating persons with LTBI among intending 
immigrants may need further evaluation.
Second, given the high prevalence of reactivation disease among persons from high burden 
countries now living in the USA and UK, a well-coordinated system of identification, 
reporting and treatment of persons with latent TB should now be considered. In the past, 
concerns about the safety, cost and logistics of effectively implementing this programme 
was perceived as a major barrier.41 The availability of a safe and cost-effective 12-dose 
regimen of weekly rifapentine plus isoniazid (3HP)44 could be used to develop and 
implement targeted LTBI testing and treatment, especially among postarrival migrant 
populations at the highest risk of disease progression.
Finally, rising or non-declining incidence among segments of the native-born population 
should be recognised as a potential threat to the gains made in TB control over the past few 
decades. In this regard, a greater understanding of the epidemiology and potential 
transmission pathways among native-born groups, including native-born Asians in the USA 
and all minority ethnic groups in the UK, is crucial. These efforts, as well as those that 
would shore up TB surveillance and prevention efforts among the entire population, will 
require greater investments in TB control. Therefore, increased funding for TB control 
activities at all levels must remain high policy priorities.
For this analysis, we recorded self-reported race and ethnicity groups to allow comparisons 
between the two countries. Doing so may have masked some important factors—including 
certain subpopulation groups driving the rate trends. Methods of HIV data collection, coding 
and linkage to the TB surveillance system were different and may have affected estimates of 
HIV coinfection in our analysis. For example, HIV testing data for most of the USA has 
detailed information that allows for estimating the coverage for HIV testing (49.8% in 2000 
and 82.5% in 2011). This calculation is not possible for the UK where only HIV positive 
cases are reported and the number tested negative are unknown.
During the period 2000–2011, TB trends declined in the USA and increased in the UK. 
While UK will benefit from a re-evaluation and improvement of its national TB control 
efforts, the USA will be well served by a continued improvement of existing control 
practices, especially those that focus on foreign-born persons and vulnerable native-born 
populations. It is our hope that lessons learnt from TB resurgence in the 1980s, which was 
preceded by a period of sustained decline, would help keep TB control funding at levels that 
optimally supports progress towards TB elimination in both countries.45
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Key messages
What is the key question?
• Why are TB case rates decreasing in the USA but increasing in the UK?
What is the bottom line?
• During 2000–2011, the number of foreign-born TB cases in the UK increased 
by 80% whereas in the USA the number of foreign-born TB cases had decreased 
by 15%.
Why read on?
• In this study, we examined trends in the number of reported TB cases and 
incidence rates between the USA and the UK with a focus on the demographic 
and clinical characteristics that may help explain the differing trends between 
these two countries—and therefore, inform future TB prevention and control 
efforts in both countries.
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Figure 1. 
TB trends—the UK and the USA, 2000–2011.
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Figure 2. 
TB trends among the native-born—the UK and the USA, 2000–2011.
Nnadi et al. Page 14
Thorax. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
TB trends among the foreign-born—the UK and the USA, 2000–2011.
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Table 1
Demographic and selected clinical characteristics of persons with reported TB, case counts—the UK and the 
USA, 2000–2011
Characteristic UK Case counts n (%) USA Case counts n (%)
Case count, all 95 772 (100) 163 837 (100)
Age, median (IQR) 36 (26–53) 44 (29–60)
Sex
 Male 52 938 (55.3) 100 765 (61.5)
 Female 42 590 (44.5) 63 041 (38.5)
 Missing or unknown 244 (0.3) 31 (0.02)
Age group, years
 00–14 5139 (5.4) 9780 (6.0)
 15–44 56 741 (59.2) 72 895 (44.5)
 ≥45 33 892 (35.4) 81 144 (49.5)
 Missing or unknown 18 (0.0) 18 (0.0)
Origin of birth
 Native-born 25 966 (27.1) 71 704 (43.7)
 Foreign-born 61 012 (63.7) 91 679 (56.0)
 Missing or unknown 8794 (9.2) 454 (0.3)
Per cent of cases among the foreign-born (2000)* 61 47
Per cent of cases among the foreign-born (2011)* 74 63
Race/ethnicity
 Asian 37 977 (39.7) 39 723 (24.2)
 Black 22 194 (23.2) 45 021 (27.5)
 White 22 705 (23.7) 30 013 (18.3)
 Other 8676 (9.1) 48 548 (29.6)
 Missing or unknown 4220 (4.4) 532 (0.3)
History of previous TB
 Yes 6649 (6.9) 7984 (4.9)
 No 72 882 (76.1) 153 659 (93.8)
 Missing or unknown 16 241 (17.0) 2194 (1.3)
Site of disease
 Pulmonary only 44 923 (46.9) 115 291 (70.4)
 Extrapulmonary only 41 936 (43.8) 33 832 (20.7)
 Both 8568 (9.0) 14 621 (8.9)
 Missing or unknown 345 (0.4) 93 (0.1)
HIV status
 Positive 4679 (4.9) 12 498 (7.6)
 Not known to be positive 91 093 (95.1) 151 339 (92.4)
MDR-TB
 Yes 593 (1.1) 1524 (1.2)
 No 52 959 (97.9) 123 011 (98.3)
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Characteristic UK Case counts n (%) USA Case counts n (%)
 Unknown 572 (1.1) 666 (0.5)
Top five countries of foreign birth*
 Mexico – 21 674 (23.7)
 Philippines – 10 206 (11.2)
 Vietnam – 7212 (7.9)
 India 14 178 (24.1) 6897 (7.5)
 China – 4579 (5.0)
 Pakistan 10 421 (17.8) –
 Somalia 6033 (10.3) –
 Zimbabwe 2508 (4.3) –
 Bangladesh 2456 (4.2) –
Time since entry (foreign-born)
 <2 years 13 551 (22.7) 23 149 (25.4)
 2–5 years 14 871 (24.9) 17 984 (19.7)
 6–9 years 7744 (13.0) 13 031 (14.3)
 ≥10 years 14 292 (23.9) 31 908 (34.9)
 Missing or unknown 9235 (15.5) 5256 (5.8)
Median time in years from entry to diagnosis (IQR) 4 (1–13) 6 (1–17)
*
Percentage is based on total foreign-born reported among those where place of birth is known (total foreign-born: USA 91 679, UK 61 012).
MDR-TB, multidrug-resistant TB.
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